Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 20/20 | 1.00 |
| ▸ | PIM3 | Q86V86 | 20/20 | 1.00 |
| ▸ | PIM2 | Q9P1W9 | 20/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 0.73 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213415 | 1.00 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3211737 | 0.94 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3211755 | 0.94 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3218177 | 0.93 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3218198 | 0.93 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3203765 | 0.90 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3203752 | 0.90 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3203729 | 0.89 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3203715 | 0.89 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL3223287 | 0.88 | PIM1 (1.00) | PIM1PIM3PIM2GSK3BPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | claimed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | claimed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2344474-B1 | PICOLINAMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-09-23 | — | — | EP | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8592455-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2013-11-26 | — | — | US | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM1 1/4885PIM3 3/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.